Professor Kenneth M Taylor

Publications


Journals

  • Shannon MS; Edwards MB; Long F; Taylor KM; Bagger JP; De Swiet M. (Sep 2008). Anticoagulant Management of Pregnancy following Heart Valve Replacement in the United Kingdom, 1986-2002. J HEART VALVE DIS. 17:526-532.
  • Landis RC; Taylor KM; Poston RS. (3 Jun 2008). Letter by Landis et al regarding article "Aprotinin Does Not Increase the Risk of Renal Failure in Cardiac Surgery Patients". CIRCULATION. 117:E473-E473. DOI.
  • Evans BJ; Haskard DO; Finch JR; Hambleton IR; Landis RC; Taylor KM. (May 2008). The inflammatory effect of cardiopulmonary bypass on leukocyte extravasation in vivo. J THORAC CARDIOV SUR. 135:999-1006. DOI.
  • Taylor KM. (Nov 1998). Central nervous system effects of cardiopulmonary bypass. ANN THORAC SURG. 66:S20-S24.
  • Bagger JP; Edwards MB; Taylor KM. (Feb 2008). Influence of socioeconomic status on survival after primary aortic or mitral valve replacement. Heart. 94:182-185. DOI.
  • Haverich A; Shernan SK; Levy JH; Chen JC; Carrier M; Taylor KM; Van de Werf F; Newman MF; et alAdams PX; Todaro TG; van der Laan M; Verrier ED. (Aug 2006). Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. ANN THORAC SURG. 82:486-493. DOI.
  • Day JR; Landis RC; Taylor KM. (Jun 2006). Aprotinin and the protease-activated receptor 1 thrombin receptor: antithrombosis, inflammation, and stroke reduction. Semin Cardiothorac Vasc Anesth. 10:132-142. DOI.
  • Zindrou D; Taylor KM; Bagger JP. (Apr 2006). Coronary artery size and disease in UK South Asian and Caucasian men. Eur J Cardiothorac Surg. 29:492-495. DOI.
  • Lockwood GG; Franks NP; Downie NA; Taylor KM; Maze M. (Mar 2006). Feasibility and safety of delivering xenon to patients undergoing coronary artery bypass graft surgery while on cardiopulmonary bypass: phase I study. Anesthesiology. 104:458-465.
  • Day JR; Haskard DO; Taylor KM; Landis RC. (Feb 2006). Effect of aprotinin and recombinant variants on platelet protease-activated receptor 1 activation. Ann Thorac Surg. 81:619-624. DOI.
  • Carrier M; Menasche P; Levy JH; Newman MF; Taylor KM; Haverich A; Chen JC; Shernan SK; et alVan de Werf F; van der Laan M; Todaro TG; Adams PX; Verrier ED. (Feb 2006). Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery. J THORAC CARDIOV SUR. 131:352-356. DOI.
  • Day JR; Taylor KM; Lidington EA; Mason JC; Haskard DO; Randi AM; Landis RC. (Jan 2006). Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. J Thorac Cardiovasc Surg. 131:21-27. DOI.
  • Edwards MB; Ordidge RJ; Hand JW; Taylor KM; Young IR. (Aug 2005). Assessment of magnetic field (4.7 T) induced forces on prosthetic heart valves and annuloplasty rings. J Magn Reson Imaging. 22:311-317. DOI.
  • Ambler G; Omar RZ; Royston P; Kinsman R; Keogh BE; Taylor KM. (12 Jul 2005). Generic, simple risk stratification model for heart valve surgery. CIRCULATION. 112:224-231. DOI.
  • Edwards MB; Draper ER; Hand JW; Taylor KM; Young IR. (2005). Mechanical testing of human cardiac tissue: some implications for MRI safety. J Cardiovasc Magn Reson. 7:835-840.
  • Day JR; Taylor KM. (2005). The systemic inflammatory response syndrome and cardiopulmonary bypass. Int J Surg. 3:129-140. DOI.
  • Day JR; Punjabi PP; Randi AM; Haskard DO; Landis RC; Taylor KM. (26 Oct 2004). Clinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery. Circulation. 110:2597-2600. DOI.
  • Puvimanasinghe JPA; Takkenberg JJM; Edwards MB; Eijkemans MJC; Steyerberg EW; van Herwerden LA; Taylor KM; Grunkemeier GL; et alHabbema JDF; Bogers AJJC. (Oct 2004). Comparison of outcomes after aortic valve replacement with a mechanical valve or a bioprosthesis using microsimulation. HEART. 90:1172-1178. DOI.
  • Edwards MB; Taylor KM. (Aug 2004). Outcomes in nonagenerians after open heart operation - Reply. ANN THORAC SURG. 78:755-755.
  • Day JR; Malik IS; Weerasinghe A; Poullis M; Nadra I; Haskard DO; Taylor KM; Landis RC. (Jul 2004). Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention. Heart. 90:794-799. DOI.
  • Omar RZ; Ambler G; Royston P; Eliahoo J; Taylor KM. (Jun 2004). Cardiac surgery risk modeling for mortality: A review of current practice and suggestions for improvement. ANN THORAC SURG. 77:2232-2237. DOI.
  • Verrier ED; Shernan SK; Taylor KM; Van de Werf F; Newman MF; Chen JC; Carrier M; Haverich A; et alMalloy KJ; Adams PX; Todaro TG; Mojcik CF; Rollins SA; Levy JH; PRIMO-CABG Investigators. (19 May 2004). Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass - A randomized trial. JAMA-J AM MED ASSOC. 291:2319-2327.
  • Tan PH; Chan C; Xue SA; Dong R; Ananthesayanan B; Manunta M; Kerouedan C; Cheshire NJ; et alWolfe JH; Haskard DO; Taylor KM; George AJ. (Apr 2004). Phenotypic and functional differences between human saphenous vein (HSVEC) and umbilical vein (HUVEC) endothelial cells. Atherosclerosis. 173:171-183. DOI.
  • Stefanou DC; Asimakopoulos G; Yagnik DR; Haskard DO; Anderson JR; Philippidis P; Landis RC; Taylor KM. (Mar 2004). Monocyte Fc gamma receptor expression in patients undergoing coronary artery bypass grafting. Ann Thorac Surg. 77:951-955. DOI.
  • Bagger JP; Zindrou D; Taylor KM. (28 Feb 2004). Postoperative infection with meticillin-resistant Staphylococcus aureus and socioeconomic background. Lancet. 363:706-708. DOI.
  • Day JR; Landis RC; Taylor KM. (Feb 2004). Heparin is much more than just an anticoagulant. J Cardiothorac Vasc Anesth. 18:93-100.
  • Philippidis P; Mason JC; Evans BJ; Nadra I; Taylor KM; Haskard DO; Landis RC. (9 Jan 2004). Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res. 94:119-126. DOI.
  • Gourlay T; Taylor KM. (2004). Untitled. PERFUSION-UK. 19:83-83. DOI.
  • Bagger JP; Zindrou D; Taylor KM. (1 Dec 2003). Leukocyte count: a risk factor for coronary artery bypass graft mortality. Am J Med. 115:660-663.
  • Omar RZ; Morton LS; Murad S; Taylor KM. (Sep 2003). Use of flexibility tests in the manufacturing process of 60 degrees Björk-Shiley convexo-concave valves and the risk of outlet strut fracture. J Thorac Cardiovasc Surg. 126:832-836.
  • Edwards MB; Taylor KM. (Aug 2003). Is 30-day mortality an adequate outcome statistic for patients considering heart valve replacement?. Ann Thorac Surg. 76:482-485.
  • Taylor KM. (Jul 2003). The Edinburgh heart valve study. HEART. 89:697-698.
  • Asimakopoulos G; Al-Ruzzeh S; Ambler G; Omar RZ; Punjabi P; Amrani M; Taylor KM. (Jun 2003). An evaluation of existing risk stratification models as a tool for comparison of surgical performances for coronary artery bypass grafting between institutions. Eur J Cardiothorac Surg. 23:935-941.
  • Tan PH; Manunta M; Ardjomand N; Xue SA; Larkin DF; Haskard DO; Taylor KM; George AJ. (Apr 2003). Antibody targeted gene transfer to endothelium. J Gene Med. 5:311-323. DOI.
  • Samankatiwat P; Samartzis I; Lertsithichai P; Stefanou D; Punjabi PP; Taylor KM; Gourlay T. (Apr 2003). Leucocyte depletion in cardiopulmonary bypass: a comparison of four strategies. Perfusion. 18:95-105.
  • Gourlay T; Samartzis I; Taylor KM. (Apr 2003). The effect of haemodilution on blood-biomaterial contact-mediated CD11b expression on neutrophils: ex vivo studies. Perfusion. 18:87-93.
  • Edwards MB; Taylor KM. (Mar 2003). Outcomes in nonagenarians after heart valve replacement operation. Ann Thorac Surg. 75:830-834.
  • Zindrou D; Taylor KM; Bagger JP. (Dec 2002). Excess coronary artery bypass graft mortality among women with hypothyroidism. Ann Thorac Surg. 74:2121-2125.
  • Edwards MB; Ordidge RJ; Thomas DL; Hand JW; Taylor KM. (Dec 2002). Translational and rotational forces on heart valve prostheses subjected ex vivo to a 4.7-T MR system. J Magn Reson Imaging. 16:653-659. DOI.
  • Zindrou D; Taylor KM; Bagger JP. (2 Nov 2002). Perioperative transfusion in anaemic patients undergoing coronary artery bypass - Reply. LANCET. 360:1427-1428.
  • Day JR; Chaudhry AN; Hunt I; Taylor KM. (Nov 2002). Heparin-induced hyperkalemia after cardiac surgery. Ann Thorac Surg. 74:1698-1700.
  • Morton L; Murad S; Omar RZ; Taylor K. (Nov 2002). Importance of emergency identification schemes. Emerg Med J. 19:584-586.
  • Zindrou D; Taylor KM; Bagger JP. (18 May 2002). Preoperative haemoglobin concentration and mortality rate after coronary artery bypass surgery. Lancet. 359:1747-1748. DOI.
  • Gourlay T; Ballaux PK; Draper ER; Taylor KM. (May 2002). Early experience with a new technique and technology designed for the study of pulsatile cardiopulmonary bypass in the rat. Perfusion. 17:191-198.
  • Nair KS; Lawrence DR; Punjabi PP; Taylor KM. (May 2002). Indications for cardiopulmonary bypass in non-cardiac operations. Perfusion. 17:161-166.
  • Gourlay T; Stefanou D; Taylor KM. (Jan 2002). The effect of methanol washing of plasticized polyvinyl chloride on biomaterial-contact-mediated CD11b (mac-1) expression in a rat recirculation model. Artif Organs. 26:5-9.
  • Wyse RK; Taylor KM. (2002). Using the STS and multinational cardiac surgical databases to establish risk-adjusted benchmarks for clinical outcomes. Heart Surg Forum. 5:258-264.
  • Landis RC; Asimakopoulos G; Poullis M; Haskard DO; Taylor KM. (Dec 2001). The antithrombotic and antiinflammatory mechanisms of action of aprotinin. Ann Thorac Surg. 72:2169-2175.
  • Landis RC; Haskard DO; Taylor KM. (Nov 2001). New antiinflammatory and platelet-preserving effects of aprotinin. Ann Thorac Surg. 72:S1808-S1813.
  • Zindrou D; Taylor KM; Bagger JP. (Sep 2001). Admission plasma glucose: an independent risk factor in nondiabetic women after coronary artery bypass grafting. Diabetes Care. 24:1634-1639.
  • Poullis M; Landis RC; Taylor KM. (Sep 2001). Aprotinin: is it prothrombotic?. Perfusion. 16:401-409.
  • Edwards MB; Taylor KM. (25 Aug 2001). Cohort survey of heart valve replacement patients: does the valve card scheme have room for improvement?. BMJ. 323:429-430.
  • Landis RC; Taylor KM. (Aug 2001). Aprotinin administration in the pericardial cavity does not prevent platelet activation. J THORAC CARDIOV SUR. 122:405-405.
  • Landis RC; Taylor KM. (Aug 2001). Aprotinin administration in the pericardial cavity does not prevent platelet activation. J Thorac Cardiovasc Surg. 122:405-406.
  • Zindrou D; Bagger JP; Smith P; Taylor KM; Ratnatunga CP. (1 Aug 2001). Comparison of operative mortality after coronary artery bypass grafting in Indian subcontinent Asians versus Caucasians. Am J Cardiol. 88:313-316.
  • Zindrou D; Bagger JP; Smith P; Taylor KM; Ratnatunga CP. (1 Aug 2001). Comparison of operative mortality after coronary artery bypass grafting in Indian subcontinent Asians versus Caucasians. AM J CARDIOL. 88:313-+.
  • Asimakopoulos G; Lidington EA; Mason J; Haskard DO; Taylor KM; Landis RC. (Jul 2001). Effect of aprotinin on endothelial cell activation. J Thorac Cardiovasc Surg. 122:123-128. DOI.
  • Omar RZ; Morton LS; Halliday DA; Danns EM; Beirne MT; Blot WJ; Taylor KM. (Jul 2001). Outlet strut fracture of Björk-Shiley convexo concave heart valves: the UK cohort study. Heart. 86:57-62.
  • Weerasinghe A; Hornick P; Smith P; Taylor K; Ratnatunga C. (Jun 2001). Coronary artery bypass grafting in non-dialysis-dependent mild-to-moderate renal dysfunction. J Thorac Cardiovasc Surg. 121:1083-1089. DOI.
  • Omar RZ; Morton LS; Beirne M; Blot WJ; Lawford PV; Hose R; Taylor KM. (Jun 2001). Outlet strut fracture of Björk-Shiley convexo-concave valves: can valve-manufacturing characteristics explain the risk?. J Thorac Cardiovasc Surg. 121:1143-1149. DOI.
  • Gourlay T; Stefanou DC; Asimakopoulos G; Taylor KM. (Jun 2001). The effect of circuit surface area on CD11b(mac-1) expression in a rat recirculation model. Artif Organs. 25:475-479.
  • Ohri SK; Parratt R; White T; Becket J; Brannan JJ; Hunt BJ; Taylor KM. (May 2001). A genetically engineered human Kunitz protease inhibitor with increased kallikrein inhibition in an ovine model of cardiopulmonary bypass. Perfusion. 16:199-206.
  • Blot WJ; Omar RZ; Kallewaard M; Morton LS; Fryzek JP; Ibrahim MA; Acheson D; Taylor KM; et alvan der Graaf Y. (Mar 2001). Risks of fracture of Björk-Shiley 60 degree convexo-concave prosthetic heart valves: long-term cohort follow up in the UK, Netherlands and USA. J Heart Valve Dis. 10:202-209.
  • Landis RC; Asimakopoulos G; Poullis M; Thompson R; Nourshargh S; Haskard DO; Taylor KM. (2001). Effect of aprotinin (trasylol) on the inflammatory and thrombotic complications of conventional cardiopulmonary bypass surgery. Heart Surg Forum. 4 Suppl 1:S35-S39.
  • Stefanou DC; Gourlay T; Asimakopoulos G; Taylor KM. (Jan 2001). Leucodepletion during cardiopulmonary bypass reduces blood transfusion and crystalloid requirements. Perfusion. 16:51-58.
  • Punjabi PP; Wyse RK; Taylor KM. (Dec 2000). Role of aprotinin in the management of patients during and after cardiac surgery. Expert Opin Pharmacother. 1:1353-1365. DOI.
  • Asimakopoulos G; Taylor KM; Haskard DO; Landis RC. (Nov 2000). Inhibition of neutrophil L-selectin shedding: a potential anti-inflammatory effect of aprotinin. Perfusion. 15:495-499.
  • Asimakopoulos G; Omar R; Bassett P; Taylor KM. (31 Oct 2000). Validation of the ACC/AHA risk stratification system and comparison with the Parsonnett system and with the EuroSCORE in patients undergoing elective isolated CABG. CIRCULATION. 102:648-648.
  • Asimakopoulos G; Thompson R; Nourshargh S; Lidington EA; Mason JC; Ratnatunga CP; Haskard DO; Taylor KM; et alLandis RC. (Aug 2000). An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. J Thorac Cardiovasc Surg. 120:361-369. DOI.
  • Edwards MB; Taylor KM; Shellock FG. (Aug 2000). Prosthetic heart valves: evaluation of magnetic field interactions, heating, and artifacts at 1.5 T. J Magn Reson Imaging. 12:363-369.
  • Poullis M; Manning R; Laffan M; Haskard DO; Taylor KM; Landis RC. (Aug 2000). The antithrombotic effect of aprotinin: actions mediated via the proteaseactivated receptor 1. J Thorac Cardiovasc Surg. 120:370-378. DOI.
  • Morton L; Omar R; Carroll S; Beirne M; Halliday D; Taylor KM. (Jun 2000). Incomplete and inaccurate death certification--the impact on research. J Public Health Med. 22:133-137.
  • Wyse RK; Taylor KM. (May 2000). Prospective development of a cardiac surgical registry. Heart Lung Circ. 9:23-26. DOI.
  • Asimakopoulos G; Kohn A; Stefanou DC; Haskard DO; Landis RC; Taylor KM. (Apr 2000). Leukocyte integrin expression in patients undergoing cardiopulmonary bypass. Ann Thorac Surg. 69:1192-1197.
  • Asimakopoulos G; Taylor KM. (Jan 2000). Octogenarians and cardiac surgery. ANN THORAC SURG. 69:317-318.
  • Griselli M; Herbert J; Hutchinson WL; Taylor KM; Sohail M; Krausz T; Pepys MB. (20 Dec 1999). C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 190:1733-1740.
  • Griselli M; Herbert J; Hutchinson WL; Taylor KM; Sohail M; Krausz T; Pepys MB. (20 Dec 1999). C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J EXP MED. 190:1733-1739.
  • Asimakopoulos G; Thompson RD; Nourshargh S; Lidington EA; Mason JC; Ratnatunga CP; Haskard DO; Taylor KM; et alLandis RC. (2 Nov 1999). Aprotinin inhibits leukocyte transmigration across endothelium. CIRCULATION. 100:611-611.
  • Ballaux PK; Gourlay T; Ratnatunga CP; Taylor KM. (Nov 1999). A literature review of cardiopulmonary bypass models for rats. Perfusion. 14:411-417.
  • Edwards MB; Taylor KM. (Nov 1999). A profile of valve replacement surgery in the UK (1986-1997): a study from the UK Heart Valve Registry. J Heart Valve Dis. 8:697-701.
  • Taylor KM. (Sep 1999). A practical affair. J THORAC CARDIOV SUR. 118:394-403.
  • Taylor KM. (Sep 1999). Honored Guest's Address. A practical affair. J Thorac Cardiovasc Surg. 118:394-403.
  • Asimakopoulos G; Smith PL; Ratnatunga CP; Taylor KM. (Sep 1999). Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass. Ann Thorac Surg. 68:1107-1115.
  • Wyse RKH; Taylor KM. (Jul 1999). The development of an International Surgical Registry: the ECSUR Project. EUR J CARDIO-THORAC. 16:2-8.
  • Wyse RK; Taylor KM. (Jul 1999). The development of an international surgical registry: the ECSUR project. The European Cardiac Surgical Registry. Eur J Cardiothorac Surg. 16:2-8.
  • Asimakopoulos G; Taylor KM; Ratnatunga CP. (Apr 1999). Outcome of coronary endarterectomy: a case-control study. Ann Thorac Surg. 67:989-993.
  • Prior FGR; Morecroft V; Fergusson R; Gourlay T; Taylor KM. (Mar 1999). Oedema, Starling and pulse reverse osmosis: towards a possible biochemical marker for oedema. INT J ARTIF ORGANS. 22:138-144.
  • Asimakopoulos G; Taylor KM; Smith PL; Ratnatunga CP. (Mar 1999). Prevalence of acute respiratory distress syndrome after cardiac surgery. J Thorac Cardiovasc Surg. 117:620-621.
  • Weerasinghe A; Edwards MB; Taylor KM. (9 Feb 1999). First redo heart valve replacement: a 10-year analysis. Circulation. 99:655-658.
  • Asimakopoulos G; Taylor KM. (Dec 1998). Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecules. Ann Thorac Surg. 66:2135-2144.
  • Weerasinghe A; Taylor KM. (Dec 1998). The platelet in cardiopulmonary bypass. Ann Thorac Surg. 66:2145-2152.
  • Ratnatunga CP; Edwards MB; Dore CJ; Taylor KM. (Dec 1998). Tricuspid valve replacement: UK Heart Valve Registry mid-term results comparing mechanical and biological prostheses. Ann Thorac Surg. 66:1940-1947.
  • Wilson JA; Taylor-Robinson SD; Bryant DJ; Taylor KM; Harris DN. (Sep 1998). Localised cerebral phosphorus-31 MR spectroscopy in man before and immediately after coronary bypass surgery with hypothermic cardiopulmonary bypass. Metab Brain Dis. 13:191-200.
  • Harris DN; Wilson JA; Taylor-Robinson SD; Taylor KM. (Sep 1998). Magnetic resonance spectroscopy of high-energy phosphates and lactate immediately after coronary artery bypass surgery. Perfusion. 13:328-333.
  • Edwards MB; Ratnatunga CP; Dore CJ; Taylor KM. (Aug 1998). Thirty-day mortality and long-term survival following surgery for prosthetic endocarditis: a study from the UK heart valve registry. Eur J Cardiothorac Surg. 14:156-164.
  • Taylor KM. (Apr 1998). Brain damage during cardiopulmonary bypass. Ann Thorac Surg. 65:S20-S26.
  • Harris DN; Oatridge A; Dob D; Smith PL; Taylor KM; Bydder GM. (Feb 1998). Cerebral swelling after normothermic cardiopulmonary bypass. Anesthesiology. 88:340-345.
  • Toner I; Taylor KM; Newman S; Smith PL. (Jan 1998). Cerebral functional changes following cardiac surgery: Neuropsychological and EEG assessment. Eur J Cardiothorac Surg. 13:13-20.
  • Taylor KM. (Jan 1998). Computer-controlled cardiopulmonary bypass increases jugular venous oxygen saturation during rewarming - Invited commentary. ANN THORAC SURG. 65:65-65.
  • Asimakopoulos G; Edwards MB; Taylor KM. (18 Nov 1997). Aortic valve replacement in patients 80 years of age and older: survival and cause of death based on 1100 cases: collective results from the UK Heart Valve Registry. Circulation. 96:3403-3408.
  • Renton S; Hornick P; Taylor KM; Grace PA. (Nov 1997). Rational approach to combined carotid and ischaemic heart disease. Br J Surg. 84:1503-1510.
  • Hornick PI; Brookes PA; Mason PD; Taylor KM; Yacoub MH; Rose ML; Batchelor R; Lechler RI. (15 Aug 1997). Optimizing a limiting dilution culture system for quantifying the frequency of interleukin-2-producing alloreactive T helper lymphocytes. Transplantation. 64:472-479.
  • Ohri SK; Bowles CW; Mathie RT; Lawrence DR; Keogh BE; Taylor KM. (Jul 1997). Effect of cardiopulmonary bypass perfusion protocols on gut tissue oxygenation and blood flow. Ann Thorac Surg. 64:163-170.
  • Asimakopoulos G; Edwards MB; Brannan J; Taylor KM. (May 1997). Survival and cause of death after mitral valve replacement in patients aged 80 years and over: collective results from the UK heart valve registry. Eur J Cardiothorac Surg. 11:922-928.
  • Taylor KM. (Apr 1997). Methylene blue administration in SIRS after cardiac operations - Reply. ANN THORAC SURG. 63:1213-1213.
  • Toner I; Taylor KM; Lockwood G; Newman S; Smith PL. (Feb 1997). EEG changes during cardiopulmonary bypass surgery and postoperative neuropsychological deficit: the effect of bubble and membrane oxygenators. Eur J Cardiothorac Surg. 11:312-319.
  • Prior FGR; Morecroft V; Gourlay T; Taylor KM. (Aug 1996). The therapeutic significance of pulse reverse osmosis. INT J ARTIF ORGANS. 19:487-492.
  • Ali MI; Smith PL; Brannan JJ; Taylor KM. (Jul 1996). Cerebral monitoring during cardiopulmonary bypass. Perfusion. 11:299-312.
  • Taylor KM. (Jun 1996). A cardiac surgeon's perspective. J Heart Valve Dis. 5 Suppl 1:S7-S8.
  • Taylor KM. (Jun 1996). Overview: A cardiac surgeon's perspective. J HEART VALVE DIS. 5:S7-S8.
  • Taylor KM. (Jun 1996). SIRS - The systemic inflammatory response syndrome after cardiac operations. ANN THORAC SURG. 61:1607-1608.
  • Yii M; Gourlay T; Fleming J; Matata B; Taylor KM. (May 1996). Evaluation of Carmeda bioactive surface (CBAS), Duraflo II and a novel nonspecific protease-modified surface using a new in vitro model simulating cardiopulmonary bypass. Perfusion. 11:229-240.
  • Ali M; Becket J; Brannan J; Fleming J; Taylor KM. (May 1996). The effect of high dose aprotinin therapy on the systemic inflammatory response in a porcine model of cardiopulmonary bypass. Perfusion. 11:278-280.
  • Ohri SK; Paratt R; Becket JM; Brannan J; Hunt BJ; Taylor KM. (Apr 1996). Genetically engineered serine protease inhibitor for hemostasis after cardiac operations. Ann Thorac Surg. 61:1223-1230.
  • Hornick P; Harris PA; Taylor KM. (Jan 1996). Tricuspid valve replacement subsequent to previous open heart surgery. J HEART VALVE DIS. 5:20-25.
  • Nkere UU; Whawell SA; Sarraf CE; Schofield JB; Thompson JN; Taylor KM. (Dec 1995). Pericardial trauma and adhesions in relation to reoperative cardiac surgery. Thorac Cardiovasc Surg. 43:338-346. DOI.
  • Hornick P; Taylor KM. (Nov 1995). Is aprotinin safe when used in the context of profound hypothermia and circulatory arrest? A literary review. J Heart Valve Dis. 4:669-673.
  • Bowles CT; Ohri SK; Klangsuk N; Keogh BE; Yacoub MH; Taylor KM. (Jul 1995). Endotoxaemia detected during cardiopulmonary bypass with a modified Limulus amoebocyte lysate assay. Perfusion. 10:219-228.
  • HORNICK P; TAYLOR KM. (3 Jun 1995). A DIFFICULT CASE - HOW SHOULD A PATIENT PRESENTING WITH UNSTABLE ANGINA AND A RECENT STROKE BE MANAGED - PERFORM CAROTID ENDARTERECTOMY AND CORONARY-ARTERY BYPASS-SURGERY AS A SINGLE PROCEDURE. BRIT MED J. 310:1451-1452.
  • Hornick PI; Harris P; Cousins C; Taylor KM; Keogh BE. (May 1995). Assessment of the value of the immediate postoperative chest radiograph after cardiac operation. Ann Thorac Surg. 59:1150-1153.
  • SLATER JD; ARNOLD JA; TAYLOR KM; BAXI S; FIELD HJ. (15 Mar 1995). FLUORESCEIN ANGIOGRAPHIC APPEARANCE OF THE NORMAL FUNDUS AND OF FOCAL CHORIORETINAL LESIONS IN THE HORSE. INVEST OPHTH VIS SCI. 36:S779-S779.
  • Hornick P; Smith PL; Taylor KM. (Nov 1994). Cerebral complications after coronary bypass grafting. Curr Opin Cardiol. 9:670-679.
  • Tousoulis D; Davies G; Crake T; Ohri SK; Rao P; Taylor KM. (Sep 1994). Left ventricular function and coronary artery disease progression early after coronary bypass grafting. Ann Thorac Surg. 58:857-863.
  • Nkere UU; Whawell SA; Sarraf CE; Schofield JB; Thompson JN; Taylor KM. (Aug 1994). Perioperative histologic and ultrastructural changes in the pericardium and adhesions. Ann Thorac Surg. 58:437-444.
  • Morgan K; Wharton J; Webb JC; Keogh BE; Smith PL; Taylor KM; Oakley CM; Polak JM; et alCleland JG. (Jul 1994). Co-expression of renin-angiotensin system component genes in human atrial tissue. J Hypertens Suppl. 12:S11-S19.
  • Toner I; Peden CJ; Hamid SK; Newman S; Taylor KM; Smith PL. (Jul 1994). Magnetic resonance imaging and neuropsychological changes after coronary artery bypass graft surgery: preliminary findings. J Neurosurg Anesthesiol. 6:163-169.
  • Ohri SK; Becket J; Brannan J; Keogh BE; Taylor KM. (May 1994). Effects of cardiopulmonary bypass on gut blood flow, oxygen utilization, and intramucosal pH. Ann Thorac Surg. 57:1193-1199.
  • Gourlay T; Taylor KM. (May 1994). Pulsatile flow and membrane oxygenators. Perfusion. 9:189-196.
  • SOMASUNDARAM S; OHRI S; DANDEKAR UD; KAGHANI A; MACPHERSON A; YACOUP MH; TAYLOR KM; MENZIES IS; et alBJARNASON I. (Apr 1994). EFFECT OF INTESTINAL HYPOPERFUSION DURING CARDIOPULMONARY BYPASS ON SMALL-INTESTINAL DISACCHARIDASE ACTIVITY. GASTROENTEROLOGY. 106:A272-A272.
  • Mazeika PK; Rees AJ; Oakley CM; Davies GJ; Taylor KM. (5 Mar 1994). Complicated myocardial infarction. BMJ. 308:643-645.
  • MAZEIKA PK; REES AJ; OAKLEY CM; DAVIES GJ; TAYLOR KM. (5 Mar 1994). GRAND ROUNDS - HAMMERSMITH-HOSPITAL - COMPLICATED MYOCARDIAL-INFARCTION - VENTRICULAR SEPTAL RUPTURE IS A SURGICAL EMERGENCY. BRIT MED J. 308:643-645.
  • Ohri SK; Bowles CT; Siddiqui A; Khaghani A; Keogh BE; Wright G; Yacoub MH; Taylor KM. (Mar 1994). The effect of cardiopulmonary bypass on gastric and colonic mucosal perfusion: a tonometric assessment. Perfusion. 9:101-108.
  • Gaer JA; Shaw AD; Wild R; Swift RI; Munsch CM; Smith PL; Taylor KM. (Feb 1994). Effect of cardiopulmonary bypass on gastrointestinal perfusion and function. Ann Thorac Surg. 57:371-375.
  • Ohri SK; Somasundaram S; Koak Y; Macpherson A; Keogh BE; Taylor KM; Menzies IS; Bjarnason I. (Feb 1994). The effect of intestinal hypoperfusion on intestinal absorption and permeability during cardiopulmonary bypass. Gastroenterology. 106:318-323.
  • Fessatidis IT; Brannan JJ; Taylor KM; Kanellaki-Kyparissi M; Abdulla AK; Olsen EC. (Jan 1994). Effect of prostacyclin PGI2 on cardiopulmonary bypass-induced lung injury. Perfusion. 9:23-33.
  • Gaer JA; Gordon L; Wharton J; Polak JM; Taylor KM; McKenna W; Parker DJ. (Dec 1993). Intractable chest pain in cardiomyopathy: treatment by a novel technique of cardiac cryodenervation with quantitative immunohistochemical assessment of success. Br Heart J. 70:574-577.
  • Taylor KM. (Nov 1993). Perioperative approaches to coagulation defects. Ann Thorac Surg. 56:S78-S82.
  • Harris DN; Bailey SM; Smith PL; Taylor KM; Oatridge A; Bydder GM. (4 Sep 1993). Brain swelling in first hour after coronary artery bypass surgery. Lancet. 342:586-587.
  • Nkere UU; Whawell SA; Thompson EM; Thompson JN; Taylor KM. (Aug 1993). Changes in pericardial morphology and fibrinolytic activity during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 106:339-345.
  • Ohri SK; Bjarnason I; Pathi V; Somasundaram S; Bowles CT; Keogh BE; Khaghani A; Menzies I; et alYacoub MH; Taylor KM. (May 1993). Cardiopulmonary bypass impairs small intestinal transport and increases gut permeability. Ann Thorac Surg. 55:1080-1086.
  • BIDSTRUP BP; HARRISON J; ROYSTON D; TAYLOR KM; TREASURE T. (Apr 1993). APROTININ THERAPY IN CARDIAC OPERATIONS - A REPORT ON USE IN 41 CARDIAC CENTERS IN THE UNITED-KINGDOM. ANN THORAC SURG. 55:971-976.
  • ARNOLD JV; GATES JWC; TAYLOR KM. (15 Mar 1993). THE MEASUREMENT OF RETINAL STRUCTURE FROM PHOTOGRAPHS - POTENTIAL SOURCE OF ERROR. INVEST OPHTH VIS SCI. 34:1169-1169.
  • Ohri SK; Nihoyannopoulos P; Taylor KM; Keogh BE. (Feb 1993). Angiosarcoma of the heart causing cardiac rupture: a rare cause of hemopericardium. Ann Thorac Surg. 55:525-528.
  • Wharton J; Gordon L; Byrne J; Herzog H; Selbie LA; Moore K; Sullivan MH; Elder MG; et alMoscoso G; Taylor KM. (15 Jan 1993). Expression of the human neuropeptide tyrosine Y1 receptor. Proc Natl Acad Sci U S A. 90:687-691.
  • Taylor KM. (Jan 1993). Improved outcome for seriously ill open heart surgery patients: focus on reoperation and endocarditis. J Heart Lung Transplant. 12:S14-S18.
  • Toner I; Hamid SK; Peden CJ; Taylor KM; Smith PL. (1993). Magnetic resonance imaging and P300 (event-related auditory evoked potentials) in the assessment of postoperative cerebral injury following coronary artery bypass graft surgery. Perfusion. 8:321-329.
  • TAYLOR KM; WALTON PKH. (12 Dec 1992). RISK STRATIFICATION FOR OPEN-HEART-SURGERY. BRIT MED J. 305:1500-1500.
  • Taylor KM. (Dec 1992). Aprotinin therapy and blood conservation: extending the indications. Br J Surg. 79:1258-1259.
  • EFSTRATIADIS T; MUNSCH C; CROSSMAN D; TAYLOR KM. (Nov 1992). HIGH-DOSE APROTININ IN EMERGENCY CORONARY-ARTERY BYPASS AFTER THROMBOLYSIS - REPLY. ANN THORAC SURG. 54:1022-1023.
  • Taylor KM; Gray SA; Livingstone S; Brannan JJ. (Nov 1992). The United Kingdom Heart Valve Registry. J Heart Valve Dis. 1:152-159.
  • Knock GA; Wharton J; Gaer JA; Yacoub MH; Taylor KM; Polak JM. (4 Sep 1992). Regional distribution and regulation of [125I]calcitonin gene-related peptide binding sites in coronary arteries. Eur J Pharmacol. 219:415-425.
  • Gourlay T; Fleming J; Taylor KM. (Jul 1992). The effects of pulsatile flow on the leukocyte depleting qualities of the Pall LG6 leukocyte depleting arterial line filter: a laboratory investigation. Perfusion. 7:227-232.
  • Gourlay T; Fleming J; Taylor KM. (Apr 1992). Laboratory evaluation of the Pall LG6 leukocyte depleting arterial line filter. Perfusion. 7:131-140.
  • OHRI SK; HASHEMI M; KEOGH BE; TAYLOR KM. (20 Feb 1992). PANCREATIC INJURY AFTER CARDIOPULMONARY BYPASS. NEW ENGL J MED. 326:573-573.
  • Gaer JA; Wharton J; Gordon L; Swift RI; Munsch C; Inglis GC; Polak JM; Taylor KM. (1992). Cardiac denervation in the calf using cryoablation: functional evidence and regional tissue catecholamine content. Eur J Cardiothorac Surg. 6:201-208.
  • TAYLOR KM. (Nov 1991). HEART-VALVE SURGERY IN THE UNITED-KINGDOM - PRESENT PRACTICE AND FUTURE-TRENDS. BRIT HEART J. 66:335-336.
  • KEOGH BE; BIDSTRUP BP; TAYLOR KM; SAPSFORD RN. (Oct 1991). ANGIOSCOPIC EVALUATION OF INTRAVASCULAR MORPHOLOGY AFTER CORONARY ENDARTERECTOMY. ANN THORAC SURG. 52:766-772.
  • Ohri SK; Desai JB; Gaer JA; Roussak JB; Hashemi M; Smith PL; Taylor KM. (Oct 1991). Intraabdominal complications after cardiopulmonary bypass. Ann Thorac Surg. 52:826-831.
  • Pradhan MJ; Fleming JS; Nkere UU; Arnold J; Wildlevuur CR; Taylor KM. (1991). Clinical experience with heparin-coated cardiopulmonary bypass circuits. Perfusion. 6:235-242.
  • RAO PV; ROUSSAK JB; HERSHAM MJ; VENN GE; TAYLOR KM. (Oct 1990). AN UNUSUAL LEFT-VENTRICULAR MASS. J ROY SOC MED. 83:650-651.
  • Taylor KM. (Oct 1990). The hemodynamics of cardiopulmonary bypass. Semin Thorac Cardiovasc Surg. 2:300-312.
  • Arnold JV; Blauth CI; Smith PL; Jagoe JR; Wootton R; Taylor KM. (Jul 1990). Demonstration of cerebral microemboli occurring during coronary artery bypass graft surgery using fluorescein angiography. J Audiov Media Med. 13:87-90.
  • JAGOE JR; BLAUTH CI; SMITH PL; ARNOLD JV; TAYLOR KM; WOOTTON R. (Jun 1990). QUANTIFICATION OF RETINAL DAMAGE DURING CARDIOPULMONARY BYPASS - COMPARISON OF COMPUTER AND HUMAN ASSESSMENT. IEE PROC-I. 137:170-175.
  • Gourlay T; Fleming J; Taylor KM; Aslam M. (1990). Evaluation of a range of extracorporeal membrane oxygenators. Perfusion. 5:117-133.
  • Gourlay T; Aslam M; Fleming J; Taylor KM. (1990). Evaluation of the Sorin Monolyth membrane oxygenator. Perfusion. 5:209-219.
  • Blauth CI; Smith PL; Arnold JV; Jagoe JR; Wootton R; Taylor KM. (Jan 1990). Influence of oxygenator type on the prevalence and extent of microembolic retinal ischemia during cardiopulmonary bypass. Assessment by digital image analysis. J Thorac Cardiovasc Surg. 99:61-69.
  • Larkin SW; Clarke JG; Keogh BE; Araujo L; Rhodes C; Davies GJ; Taylor KM; Maseri A. (15 Oct 1989). Intracoronary endothelin induces myocardial ischemia by small vessel constriction in the dog. Am J Cardiol. 64:956-958.
  • Keogh BE; Crea F; Bull T; Blackie RA; Taylor KM. (Jul 1989). Intravascular delivery of laser energy with metal-capped optical fibers: the potential hazard of distal embolism. Am Heart J. 118:47-53.
  • CLARKE JG; LARKIN SW; BENJAMIN N; KEOGH BE; CHESTER A; DAVIES GJ; TAYLOR KM; MASERI A. (1989). ENDOTHELIN-1 IS A POTENT LONG-LASTING VASOCONSTRICTOR IN DOG PERIPHERAL VASCULATURE INVIVO. J CARDIOVASC PHARM. 13:S211-S212.
  • BIDSTRUP BP; ROYSTON D; TAYLOR KM; SAPSFORD RN. (Mar 1989). REDUCTION IN BLOOD-LOSS AND BLOOD USE AFTER CARDIOPULMONARY BYPASS WITH HIGH-DOSE APROTININ (TRASYLOL). J THORAC CARDIOV SUR. 97:364-372.
  • BIDSTRUP BP; ROYSTON D; SAPSFORD RN; TAYLOR KM. (Jan 1989). EFFECT OF APROTININ ON BLOOD CONSERVATION DURING CARDIAC-SURGERY. BRIT HEART J. 61:111-111.
  • Clarke JG; Larkin SW; Benjamin N; Keogh BE; Chester A; Davies GJ; Taylor KM; Maseri A. (1989). Endothelin-1 is a potent long-lasting vasoconstrictor in dog peripheral vasculature in vivo. J Cardiovasc Pharmacol. 13 Suppl 5:S211-S212.
  • KEOGH BE; CREA F; BULL T; PASHAZADEH M; BLACKIE RAS; FOALE RA; DAVIES GJ; KIDNER PH; et alDAVIES MJ; TAYLOR KM. (Jan 1989). LASER THERMAL ANGIOPLASTY - LIMITATIONS IN THE CORONARY CIRCULATION. BRIT HEART J. 61:86-86.
  • Blauth C; Smith P; Newman S; Arnold J; Siddons F; Harrison MJ; Treasure T; Klinger L; et alTaylor KM. (1989). Retinal microembolism and neuropsychological deficit following clinical cardiopulmonary bypass: comparison of a membrane and a bubble oxygenator. A preliminary communication. Eur J Cardiothorac Surg. 3:135-138.
  • NADAZDIN A; KAMBOUROGLOU D; JOSHI J; NIHOYANNOPOULOS P; SMITH P; TAYLOR KM. (Oct 1988). DOPPLER CHARACTERISTICS OF NORMAL PERICARDIAL BIOPROSTHESES. POSTGRAD MED J. 64:818-818.
  • Wharton J; Gulbenkian S; Merighi A; Kuhn DM; Jahn R; Taylor KM; Polak JM. (Oct 1988). Immunohistochemical and ultrastructural localisation of peptide-containing nerves and myocardial cells in the human atrial appendage. Cell Tissue Res. 254:155-166.
  • BLAUTH C; SMITH P; TAYLOR KM. (Sep 1988). BRAIN MICROVASCULAR FUNCTION. J THORAC CARDIOV SUR. 96:489-489.
  • Blauth CI; Arnold JV; Schulenberg WE; McCartney AC; Taylor KM. (Apr 1988). Cerebral microembolism during cardiopulmonary bypass. Retinal microvascular studies in vivo with fluorescein angiography. J Thorac Cardiovasc Surg. 95:668-676.
  • MARATH A; MAN W; TAYLOR KM; DEVERALL PB; PARSONS S; JONES OH; LINCOLN C; KIMBERLEY A. (Apr 1988). PLASMA HISTAMINE PROFILES IN PEDIATRIC CARDIOPULMONARY BYPASS. AGENTS ACTIONS. 23:339-342.
  • MARATH A; RICHARDS P; MAN W; TAYLOR KM; LINCOLN C; SONI N; RICEEDWARDS JM; BARTOLI A; et alGLADSTONE D. (Apr 1988). THE CLINICAL-SIGNIFICANCE OF ELEVATED CSF AND PLASMA HISTAMINE IN CEREBRAL ANEURYSM SURGERY UTILIZING CARDIOPULMONARY BYPASS WITH TOTAL CIRCULATORY ARREST. AGENTS ACTIONS. 23:343-347.
  • Meleagros L; Ghatei MA; Anderson JV; Wharton J; Taylor KM; Krikler DM; Meijler FL; Polak JM; et alBloom SR. (15 Mar 1988). The presence and molecular forms of cardiodilatin immunoreactivity in the human and rat right atrium. Clin Chim Acta. 172:199-209.
  • KEOGH BE; PASHAZADEH M; CREA F; TAYLOR KM. (Feb 1988). LASER ENDARTERECTOMY AND ANGIOPLASTY - A CAUTIONARY NOTE. J THORAC CARDIOV SUR. 95:351-351.
  • Crea F; Davies G; McKenna WJ; Pashazadeh M; Keogh B; Kidner P; Taylor KM; Maseri A. (Feb 1988). Laser recanalisation of coronary arteries by metal-capped optical fibres: early clinical experience in patients with stable angina pectoris. Br Heart J. 59:168-174.
  • ROADS E; TAYLOR KM. (Feb 1988). MORE RESEARCH INVOLVEMENT FOR NURSES. BRIT J HOSP MED. 39:170-170.
  • KEOGH BE; OAKLEY CM; TAYLOR KM. (Jan 1988). CHRONIC CONSTRICTIVE PERICARDITIS CAUSED BY SELF-MUTILATION WITH SEWING NEEDLES - A CASE-REPORT AND REVIEW OF PUBLISHED REPORTS. BRIT HEART J. 59:77-80.
  • KEOGH BE; TAYLOR KM. (1988). LASER CORONARY REVASCULARIZATION. CURR OPIN CARDIOL. 3:901-908.
  • KEOGH BE; TAYLOR KM. (Jul 1987). THE PITFALLS OF LASER CORONARY ANGIOPLASTY RESEARCH. BRIT J HOSP MED. 38:81-81.
  • CREA F; KASKI JC; FRAGASSO G; HACKETT D; STANBRIDGE R; TAYLOR KM; MASERI A. (1 Jul 1987). USEFULNESS OF HOLTER MONITORING TO IMPROVE THE SENSITIVITY OF EXERCISE TESTING IN DETERMINING THE DEGREE OF MYOCARDIAL REVASCULARIZATION AFTER CORONARY-ARTERY BYPASS-GRAFTING FOR STABLE ANGINA-PECTORIS. AM J CARDIOL. 60:40-43.
  • TAYLOR KM. (Jun 1987). ASSESSING THE RISK OF CORONARY SURGERY. BRIT J HOSP MED. 37:557-557.
  • MARATH A; MAN W; TAYLOR KM. (Apr 1987). HISTAMINE-RELEASE IN PEDIATRIC CARDIOPULMONARY BYPASS - A POSSIBLE ROLE IN THE CAPILLARY LEAK SYNDROME. AGENTS ACTIONS. 20:299-302.
  • NOLOP KB; BRAUDE S; TAYLOR KM; ROYSTON D. (Mar 1987). EPITHELIAL AND ENDOTHELIAL FLUX AFTER BYPASS IN DOGS - EFFECT OF POSITIVE END-EXPIRATORY PRESSURE. J APPL PHYSIOL. 62:1244-1249.
  • CREA F; DAVIES G; MCKENNA WJ; PASHAZADEH M; KIDNER P; TAYLOR KM; MASERI A. (Jan 1987). PERCUTANEOUS LASER RECANALIZATION OF CORONARY-ARTERIES IN MAN - EARLY RESULTS. BRIT HEART J. 57:87-88.
  • NIHOYANNOPOULOS P; FOALE RA; SMITH GC; OAKLEY CM; TAYLOR KM. (Jan 1987). THE ECHOCARDIOGRAPHIC DOPPLER DESCRIPTION OF PERICARDIAL PROSTHESES AND THE POTENTIAL IN LONG-TERM FOLLOW-UP. BRIT HEART J. 57:107-107.
  • BRAUDE S; NOLOP KB; FLEMING JS; KRAUSZ T; TAYLOR KM; ROYSTON D. (Nov 1986). INCREASED PULMONARY TRANS-VASCULAR PROTEIN FLUX AFTER CANINE CARDIOPULMONARY BYPASS - ASSOCIATION WITH LUNG NEUTROPHIL SEQUESTRATION AND TISSUE PEROXIDATION. AM REV RESPIR DIS. 134:867-872.
  • BLAUTH C; ARNOLD J; KOHNER EM; TAYLOR KM. (11 Oct 1986). RETINAL MICROEMBOLISM DURING CARDIOPULMONARY BYPASS DEMONSTRATED BY FLUORESCEIN ANGIOGRAPHY. LANCET. 2:837-839.
  • JANI K; CARLI F; BIDSTRUP BP; ROYSTON D; TAYLOR KM. (Jul 1986). CHANGES IN BODY-TEMPERATURE FOLLOWING CARDIOPULMONARY BYPASS PROCEDURES - THE EFFECTS OF ACTIVE REWARMING. LIFE SUPPORT SYST. 4:269-272.
  • ROYSTON D; FLEMING JS; DESAI JB; WESTABY S; TAYLOR KM. (May 1986). INCREASED PRODUCTION OF PEROXIDATION PRODUCTS ASSOCIATED WITH CARDIAC OPERATIONS - EVIDENCE FOR FREE-RADICAL GENERATION. J THORAC CARDIOV SUR. 91:759-766.
  • MAN WK; BRANNAN JJ; FESSATIDIS I; BECKETT J; TAYLOR KM. (Apr 1986). EFFECT OF PROSTACYCLIN ON THE CIRCULATORY HISTAMINE DURING CARDIOPULMONARY BYPASS. AGENTS ACTIONS. 18:182-185.
  • Taylor KM. (Mar 1986). Pathophysiology of brain damage during open-heart surgery. Tex Heart Inst J. 13:91-96.
  • FOALE R; ROWLAND E; NIHOYANNOPOULOS P; WEBB S; PERELMAN M; TAYLOR KM; KRIKLER DM. (1985). CONTRAST ECHOCARDIOGRAPHIC EFFECT AFTER ENDOCAVITARY ABLATION. CLIN SCI. 68:P57-P58.
  • FOALE R; ROWLAND E; NIHOYANNOPOULOS P; WEBB S; PERELMAN M; TAYLOR KM; KRIKLER DM. (1985). CONTRAST EFFECT AFTER ENDOCAVITARY ABLATION. J AM COLL CARDIOL. 5:454-454.
  • FESSATIDIS I; MAN W; BRANNAN JJ; TAYLOR KM. (1985). HEMODYNAMIC AND HEMATOLOGICAL EFFECTS OF PROSTACYCLIN INFUSION. BRIT J SURG. 72:1032-1032.
  • TAYLOR KM. (1983). EFFECT OF PULSATILE FLOW DURING CARDIOPULMONARY BYPASS. J THORAC CARDIOV SUR. 86:454-455.

Conferences

  • TAYLOR KM. PULSATILE AND NONPULSATILE PERFUSION. 2ND SYMP ON CARDIO-THORACIC SURGERY : WHAT IS NEW IN CURRENT PRACTICE. 985:57-65. (1992).
  • MAN WK; MARATH A; OJUKWU J; DEVERALL P; TAYLOR KM. EFFECT OF MYOCARDIAL PROTECTION ON PLASMA HISTAMINE IN THE CARDIOTOMY SUCTION EFFLUENT DURING CARDIOPULMONARY BYPASS IN OPEN-HEART-SURGERY. 21ST ANNUAL MEETING OF THE EUROPEAN HISTAMINE RESEARCH SOC. 38:C275-C277. (1993).
  • TAYLOR KM. THE FUTURE OF PERFUSION RESEARCH. 14th Annual Seminar on Cardiovascular Perfusion of the American-Academy-of-Cardiovascular-Perfusion. 14:164-168. (1993).
  • Hornick P; Taylor KM. The inflammatory response to cardiopulmonary bypass. 7th Annual Meeting on Cardiac Surgery - Current Issues. 4:25-44. (1995).
  • Hornick P; Brookes P; Mason P; Taylor KM; Yacoub MY; Batchelor JR; Rose M; Lechler RI. Limiting dilution analysis: increasing the sensitivity and specificity of the alloreactive T helper cell assay by abrogating unwanted IL-2 production. 12th International Histocompatibility Conference - HLA. 557-560. (1997).
  • Hoare GS; Al-Ruzzeh S; Asimakopoulos G; Taylor KM; Amrani M; Marczin N. Off-pump and on-pump coronary surgery exhibit a similar anti-inflammatory cytokine profile. American-Heart-Association Abstracts From Scientific Sessions. 106:344-344. (5 Nov 2002).
  • Ambler G; Omar RZ; Royston P; Taylor KM. A risk score for predicting short-term mortality following heart valve surgery. 76th Annual Scientific Session of the American-Heart-Association. 108:755-756. (28 Oct 2003).
  • Omar RZ; Ambler G; Royston P; Taylor KM. Impact of missing predictor values on risk stratification models in cardiac surgery. 6th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke. 111:E337-E337. (24 May 2005).
  • Landis C; Philippidis P; Boyle JJ; Domin J; Nadra I; Taylor KM; Haskard DO. Hemoglobin scavenging (CD163+) macrophages in atherosclerosis: an anti-inflammatory checkpoint?. 38th Annual Meeting of the Society-for-Leukocyte-Biology. 41-41. (2005).
  • Bagger JP; Edwards MB; Taylor KM. Influence of socioeconomic status on survival after primary aortic or mitral valve replacement. Does gender play a role?. World Congress of Cardiology. 27:833-834. (Aug 2006).
  • Birdsey GM; Amsellem V; Mason JC; Gebhardt F; Taylor KM; Haskard DO; Randi AM. The transcription factor ERG regulates angiogenesis and apoptosis. 93. (Feb 2007).
  • Landis RC; Evans BJ; Haskard D; Taylor KM. Aprotinin blocks leukocyte extravasation into tissues in patients undergoing cardio-thoracic surgery with cardiopulmonary bypass. 114:754-754. (31 Oct 2006).
  • Philippidis P; Boyle J; Domin J; Nadra I; Haskard DO; Taylor KM; Landis RC. Anti-inflammatory hemoglobin scavenging macrophages in atheroschlerotic plaques: A potential atheroprotective role. 112:U126-U126. (25 Oct 2005).
  • Carrier M; Taylor KM; Haverich A; Chen JC; Shernan SK; Newman MF; Levy JH; Van de Wert F; et alvan der Laan M; Todaro TG; Adams PX; Verrier ED. Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve procedure and coronary artery bypass surgery. 110:672-672. (26 Oct 2004).
  • Haverich A; Taylor KM; Carrier M; Chen JC; Sherman SK; Van de Werf F; Newman MF; Levy JH; et alAdams PX; Todaro TG; van der Laan M; Verrier ED. Inhibition of complement activation by pexelizurnab reduces death and myocardial infarction in cardiac surgical patients with selected risk profiles: Results from the international multi-center PRIMO-CABG study. 110:421-421. (26 Oct 2004).
  • Evans BJ; Hogg N; Taylor KM; Haskard DO; Landis RC. LFA-1 shedding from transmigrated leukocytes: A novel finding with possible implications for the role of integrins in atherogenesis. 110:253-253. (26 Oct 2004).
  • Philippidis P; Taylor KM; Haskard DO; Landis RC. Anti-inflammatory monocytes are induced following cardiopulmonary bypass surgery. 90:A29-A29. (May 2004).
  • Day JRS; Haskard DO; Taylor KM; Landis RC. Aprotinin prevents platelet dysfunction after cardiopulmonary bypass (CPB) by protecting PAR1. 90:A29-A29. (May 2004).
  • Day JRS; Malik IS; Weerasinghe A; Poullis M; Nadra I; Haskard DO; Taylor KM; Landis RC. Distinct yet complementary roles of IIB/IIIA inhibitors and heparin during platelet activation: Implications for restenosis following percutaneous coronary interventions (PCI). 90:A18-A18. (May 2004).
  • Philippidis P; Nadra I; Taylor KM; Haskard DO; Landis RC. Haemoglobin scavenging human macrophages elicit haptoglobin phenotype dependent anti-inflammatory, atheroprotective effects. 174:S5-S5. (May 2004).
  • Day JRS; Haskard D; Taylor KM; Landis RC. Recombinant aprotinin variants block platelet activation via PAR1. 90:A38-A39. (May 2004).
  • Philippidis P; Nadra I; Evans B; Taylor KM; Haskard DO; Landis RC. Susceptibility to diabetic cardiovascular disease is influenced by haptoglobin (Hp) phenotype dependent anti-inflammatory pathways in macrophages (M phi). 90:A56-A56. (May 2004).
  • Philippidis P; Mason JC; Evans B; Nadra I; Taylor KM; Haskard DO; Landis RC. The hemoglobin scavenger receptor CD163 on human macrophages is linked to athero-protective IL-10 and HO-1 effector pathways. 170:S14-S14. (Sep 2003).
  • Asimakopoulos G; Edwards MB; Brannan J; Taylor KM. Survival and cause of death after mitral valve replacement in patients aged 80 years and over - Collective results from the UK heart valve registry. 11:922-927. (May 1997).
Share this on DeliciousTweet thisDigg thisStumble thisShare this on Facebook